4th Gene Therapy Patient Engagement Summit

Patient engagement is a crucial responsibility of any gene therapy company that is serious about progressing safe, effective, and meaningful therapies to patients.

The 4th Gene Therapy Patient Engagement Summit is returning in 2024, sitting at the unique interface of patient engagement and gene therapy, from embarking on first-in-human trials through to commercial therapeutics.

Join 80+ patient advocacy and engagement professionals at gene therapy companies and patient advocacy groups to gain actionable insights that you can immediately implement into your own gene therapy programs, and come together with the community to develop solutions to the challenges that are unique to the gene therapy space.

URLs:
Website: https://go.evvnt.com/2174655-0?pid=176 
Tickets: https://go.evvnt.com/2174655-1?pid=176 
Brochure: https://go.evvnt.com/2174655-3?pid=176 

Time: 9:00 AM - 4:00 PM

Prices:
Drug Developer: Conference + Workshop Day: USD 3697.00,
Drug Developer: Conference Only: USD 2599.00,
Academic and Non-For-Profit: Conference + Workshop Day: USD 2947.00,
Academic and Non-For-Profit: Conference Only: USD 2199.00,
Solution Provider: Conference + Workshop Day: USD 4497.00,
Solution Provider: Conference Only: USD 3199.00

Speakers: Oscar Segurado, Clinical Development, ASC Therapeutics, Kara Fick, Director, Patient Advocacy and Medical Affairs, Atsena, Natacha Raphael, Head of Corporate Affairs and Patient Advocacy, Biogen Intercontinental Region, Tiara Johnson, Associate Director Global Patient Affairs Program Lead and Regulatory Patient Engagement, BioMarin Pharmaceutical, Mandy Rohrig, Director, Patient Advocacy, BridgeBio, Behtash Bahador, Director, Health Literacy, CISCRP, Paul Sommer, Global Head, Patient Experience and Innovation, Decibel Therapeutics, Christine Slater, Associate Director, Patient Recruitment, Editas Medicine, Felice Tsui, Associate Director, Patient Advocacy and Medical Affairs, Editas Medicine, Jennifer Helfer, Patient Advocacy and Engagement, Encoded Therapeutics, Craig Kessler, Professor, Georgetown University, Karen Utley, President and Co-Founder, International Foundation for CDKL5 Research, Matt Giordano, Director, Patient Services Field Operations, Krystal Biotech, Len Valentino, Chief Executive Officer, National Bleeding Disorders Foundation, Pam Rattananont, Director, US Patient Engagement, Rare Diseases, Novartis, Michaela Jones, Global Medical Affairs, Hemophilia Gene Therapy (CRISPR/ Cas9) and Thrombosis, Regeneron Pharmaceuticals, Martin Wilson, General Counsel and Chief Compliance Officer, Rocket Pharmaceuticals, Tara Hastings, Patient Engagement Lead, Sanofi, Lesley Milliner, Sr. Patient Education Liaison, Spark Therapeutics, Nan Doyle, Former Patient Insights, Rare Disease Drug Discovery Unit, Takeda, Wendy Borsari, Sr. Manager, Patient Advocacy, Tenaya Therapeutics, Kristin Voorhees, Director, Patient Advocacy, Ultragenyx